
Topic
Coverage Access
Formulary tiers, utilization management, patient support, and the access layer GoodRx and drug labels do not explain.

Pricing & Access· May 22, 2026 · 17 min read

Specialty· May 22, 2026 · 10 min read
REMS distribution design: when access controls become a specialty-pharmacy bottleneck

Biosimilars· May 22, 2026 · 10 min read
Rituxan biosimilars: FDA status, interchangeability, payer coverage, and switching
By Ran Chen#Biosimilars#Oncology#Coverage Access

Specialty· May 22, 2026 · 11 min read
Site-of-care edits for IV and subcutaneous specialty drugs

Specialty· May 22, 2026 · 11 min read
White bagging and brown bagging policies for infusion biologics
By Ran Chen#Specialty Pharmacy#Buy and Bill#Oncology

Biosimilars· May 21, 2026 · 8 min read
Eylea biosimilars: FDA status, interchangeability, launches, and payer coverage

Biosimilars· May 21, 2026 · 7 min read
Herceptin biosimilars: FDA status, payer coverage, coding, and switching
By Ran Chen#Biosimilars#Oncology#Coverage Access

Policy· May 21, 2026 · 8 min read
Medicare Part D redesign 2025-2026: IRA changes and access implications

Biosimilars· May 20, 2026 · 9 min read
Humira biosimilars compared: FDA status, interchangeability, payer coverage, and switching

Pricing & Access· May 20, 2026 · 10 min read
Mounjaro vs Zepbound: label, access, and payer coverage compared
By Ran Chen#GLP-1#Coverage Access#Prior Authorization